MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Level of serum Mortalin in Parkinson’s disease correlating with -Synuclein: Assessment of protein marker for early detection

S. Dey, A. Singh, T. Bajaj, A.B. Dey (New Delhi, India)

Meeting: 2018 International Congress

Abstract Number: 276

Keywords: Alpha-synuclein

Session Information

Date: Saturday, October 6, 2018

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: This study aims to quantify and correlate Mortalin and α-Syn protein in serum of Parkinson’s disease patients and develop it as protein marker for early detection of Parkinson’s disease.

Background: Mortalin is associated with Parkinson’s disease (PD) both physiological as well as clinical. Mortalin, a mitochondrial chaperone, plays significant role in reducing toxicity of lewy bodies. The earlier study reported lower expression of Mortalin in different models of PD patients. In PD, increased level of Mortalin suppresses the toxicity of aggregated α-Syn (1)

Methods: The expression of Mortalin and α-Syn in serum samples of 38 PD patients and 33 control group (CG) individuals were estimated by surface plasmon resonance (SPR). The receiver operating characteristic (ROC) curves were constructed to develop it as blood based protein marker. The level of Mortalin in serum was confirmed by western blot.

Results: The Mortalin level was found to be downregulated in PD patients (1.98±0.53 ng/µL) in comparison to CG individuals (3.13±0.48 ng/µL) whereas α-Syn level was found to be upregulated in PD patients (38.20±4.22ng/µL) than CG individuals (34.31±3.23 ng/µL) in serum. The negative correlation between Mortalin and α-Syn was revealed by statistical analysis

Conclusions: This preliminary study concluded that Mortalin plays a crucial role in PD with negative correlation with α-Syn. This study provides a new platform for the development of Mortalin as a potent serum protein diagnostic marker for PD.

References: 1. Zhu J., Vereshchagina N., Sreekumar V., Barbulla L.F., Costa A.C., Daub K.J., Woitalla D., Martis L.M., Kruger R., Rasse T.M., 2013. Knockdown of Hsc70-5/mortalin Induces Loss of Synaptic Mitochondria in a Drosophila Parkinson’s Dis-ease Model. PLoS ONE 8, e83714.

To cite this abstract in AMA style:

S. Dey, A. Singh, T. Bajaj, A.B. Dey. Level of serum Mortalin in Parkinson’s disease correlating with -Synuclein: Assessment of protein marker for early detection [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/level-of-serum-mortalin-in-parkinsons-disease-correlating-with-%ef%81%a1-synuclein-assessment-of-protein-marker-for-early-detection/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/level-of-serum-mortalin-in-parkinsons-disease-correlating-with-%ef%81%a1-synuclein-assessment-of-protein-marker-for-early-detection/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley